CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 536 enrolled
Drug / intervention
Mifepristonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03913104
NCT03913104Phase 4Completed
CompareCT.gov

Feasibility and Acceptability of Dispensing Mifepristone Via Mail Order Pharmacy

Daniel Grossman, MD·interventional·Posted Apr 12, 2019·Updated Aug 14, 2024

In Brief

A Phase 4 clinical trial evaluating Mifepristone for Abortion Early and Pregnancy Related. Completed, enrolled 536 participants across 11 sites.

Detailed Summary

This study aims to evaluate the feasibility, acceptability, and effectiveness of dispensing mifepristone via a mail-order pharmacy. The investigators will recruit patients at up to 10 primary care and internal medicines sites not currently providing abortion services around the country, as well as abortion clinic sites. Patients will go through routine in clinic visits to determine eligibility and then will receive the medications in the mail at their preferred address. The investigators will survey patients 3 and 14 days after the initial clinic visit and interview providers at the end of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbortion Early, Pregnancy Related
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedApr 12, 2019
Enrollment StartJan 5, 2020
Primary CompletionJul 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.2 years ago

Interventions

Mifepristonedrug

Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.